Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L3YX
|
|||
| Former ID |
DCL001009
|
|||
| Drug Name |
T-62
|
|||
| Synonyms |
40312-34-3; T-62; T62; UNII-9Q765ZIF8L; CHEMBL57997; 9Q765ZIF8L; 3-(4-chlorobenzoyl)-4,5,6,7-tetrahydro-1-benzothiophen-2-amine; (2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)(4-chlorophenyl)methanone; 2-Amino-3-(4-chlorobenzoyl)-5,6,7,8-tetrahydrobenzothiophene; (2-amino-4,5,6,7-tetrahydro-1-benzothien-3-yl)(4-chlorophenyl)methanone; (2-Amino-4,5,6,7-tetrahydro-benzo[b]thiophen-3-yl)-(4-chloro-phenyl)-methanone; BAS 01842965; AC1Q50OD; AC1LH2S9; Oprea1_104969; Oprea1_077736; SCHEMBL135569; CTK6G9061; DTXSID20193322
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Neuropathic pain [ICD-11: 8E43.0] | Discontinued in Phase 1 | [1] | |
| Therapeutic Class |
Analgesics
|
|||
| Company |
King Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H14ClNOS
|
|||
| Canonical SMILES |
C1CCC2=C(C1)C(=C(S2)N)C(=O)C3=CC=C(C=C3)Cl
|
|||
| InChI |
1S/C15H14ClNOS/c16-10-7-5-9(6-8-10)14(18)13-11-3-1-2-4-12(11)19-15(13)17/h5-8H,1-4,17H2
|
|||
| InChIKey |
OTZVBZFYMFTYKH-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 40312-34-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
1098498, 4020521, 5015910, 9168380, 14751361, 24724635, 29217669, 45844128, 47487200, 48381677, 50399255, 57408860, 89010306, 103247988, 103857411, 103980695, 105138250, 110006724, 117526639, 118265374, 124582506, 128861724, 130961476, 131359574, 142419830, 162248528, 162943975, 163640238, 167756202, 198972600, 225223475, 226503353, 241088364, 252450807
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adenosine A2a receptor (ADORA2A) | Target Info | Antagonist | [1] |
| KEGG Pathway | Rap1 signaling pathway | |||
| Calcium signaling pathway | ||||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Vascular smooth muscle contraction | ||||
| Parkinson's disease | ||||
| Alcoholism | ||||
| Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | |||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | |||
| Reactome | NGF-independant TRKA activation | |||
| Adenosine P1 receptors | ||||
| G alpha (s) signalling events | ||||
| Surfactant metabolism | ||||
| WikiPathways | Nucleotide GPCRs | |||
| Monoamine Transport | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| NGF signalling via TRKA from the plasma membrane | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.